Search

Your search keyword '"Masone, F."' showing total 20 results
Start Over Author "Masone, F."
20 results on '"Masone, F."'

6. MIBI scintigraphy in assessment of retrosternal thyroid

Author

Di Lieto E, Masone F, SANTINI, Mario, Di Crescenzo VG, Cioffi M, Pansa N, MANSI, Luigi, RAMBALDI, Pier Francesco, Di Lieto, E, Rambaldi, Pier Francesco, Masone, F, Santini, Mario, Di Crescenzo, Vg, Cioffi, M, Pansa, N, and Mansi, Luigi

Published
1998

10. Le idronefrosi neonatali: follow-up a lungo termine

Author

Lama G, Valentino L, De Rosa C, Esposito Salsano M, MARTE, Antonio, Ruocco G, CIOCE, Fabrizio, F. Masone F, MANSI, Luigi, RAMBALDI, Pier Francesco, Lama, G, Valentino, L, De Rosa, C, Esposito Salsano, M, Marte, Antonio, Ruocco, G, Cioce, Fabrizio, F., Masone F, Rambaldi, Pier Francesco, and Mansi, Luigi

Published
1997

13. I-123 thyroid uptake in congenital hypothyroidism

Author

MANSI, Luigi, Marino G, Masone F, Puntieri P, PERRONE, Laura, Stoppoloni O., RAMBALDI, Pier Francesco, Mansi, Luigi, Marino, G, Rambaldi, Pier Francesco, Masone, F, Puntieri, P, Perrone, Laura, and Stoppoloni, O.

Published
1996

19. 99mTc-Tetrofosmin in Breast Cancer: Experience of the Second University of Naples

Author

Laprovitera A, Cuccurullo, F. Masone, Luigi Mansi, Di Gregorio F, E. Procaccini, Pier Francesco Rambaldi, Mansi, Luigi, Rambaldi, Pier Francesco, Cuccurullo, Vincenzo, Laprovitera, A, DI GREGORIO, F, Masone, F, and Procaccini, Eugenio

Subjects
Adult, 99m, Oncology, Cancer Research, medicine.medical_specialty, 99mTc-tetrofosmin, Scintimammography, Breast Neoplasms, Organophosphorus Compounds, Breast cancer, Internal medicine, medicine, Humans, Radionuclide Imaging, Aged, business.industry, Tc-tetrofosmin, Organotechnetium Compounds, General Medicine, Middle Aged, medicine.disease, Lymphatic Metastasis, Female, Radiopharmaceuticals, business, Mammography
Published
1997
Full Text
View/download PDF

20. Algorithm for Reducing Overall Biological Detriment Caused by PET/CT: an Age-Based Study.

Author

Spadafora M, Sannino P, Mansi L, Mainolfi C, Capasso R, Di Giorgio E, Fiordoro S, Imbimbo S, Masone F, and Evangelista L

Abstract

Purpose: This study is to use a simple algorithm based on patient's age to reduce the overall biological detriment associated with PET/CT., Materials and Methods: A total of 421 consecutive patients (mean age 64 ± 14 years) undergoing PET for various clinical indications were enrolled. For each scan, effective dose (ED in mSv) and additional cancer risk (ACR) were computed both in a reference condition (REF) and after applying an original algorithm (ALGO). The ALGO modified the mean dose of FDG and the PET scan time parameters; indeed, a lower dose and a longer scan time were reported in the younger, while a higher dose and a shorter scan time in the older patients. Moreover, patients were classified by age bracket (18-29, 30-60, and 61-90 years)., Results: The ED was 4.57 ± 0.92 mSv in the REF condition. The ACR were 0.020 ± 0.016 and 0.0187 ± 0.013, respectively, in REF and ALGO. The ACR for the REF and ALGO conditions were significantly reduced in males and females, although it was more evident in the latter gender (all p < 0.0001). Finally, the ACR significantly reduced from the REF condition to ALGO in all three age brackets (all p < 0.0001)., Conclusion: Implementation of ALGO protocols in PET can reduce the overall ACR, mainly in young and female patients., Competing Interests: Conflict of InterestMarco Spadafora, Pasqualina Sannino, Luigi Mansi, Ciro Mainolfi, Rosario Capasso, Eugenio Di Giorgio, Salvatore Fiordoro, Serena Imbimbo, Filomena Masone, and Laura Evangelista declare no conflict of interest., (© The Author(s) 2023.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results